Sanofi Price to Free Cash Flow Ratio 2010-2024 | SNY
Historical price to free cash flow ratio values for Sanofi (SNY) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Sanofi Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-10-03 |
55.54 |
|
25.07 |
| 2024-06-30 |
48.52 |
$2.22 |
21.90 |
| 2024-03-31 |
46.65 |
$3.55 |
13.13 |
| 2023-12-31 |
47.73 |
$3.55 |
13.43 |
| 2023-09-30 |
51.49 |
$4.11 |
12.52 |
| 2023-06-30 |
51.74 |
$5.51 |
9.38 |
| 2023-03-31 |
50.34 |
$4.11 |
12.24 |
| 2022-12-31 |
44.80 |
$4.11 |
10.89 |
| 2022-03-31 |
45.96 |
0 |
0.00 |
| 2021-09-30 |
43.16 |
0 |
0.00 |
| 2021-03-31 |
42.66 |
0 |
0.00 |
| 2020-09-30 |
43.27 |
0 |
0.00 |
| 2020-03-31 |
36.39 |
0 |
0.00 |
| 2019-09-30 |
38.56 |
$2.66 |
14.51 |
| 2019-03-31 |
35.37 |
$1.78 |
19.82 |
| 2018-03-31 |
30.56 |
$2.66 |
11.50 |
| 2017-12-31 |
32.79 |
$2.66 |
12.34 |
| 2017-09-30 |
37.97 |
$2.55 |
14.91 |
| 2017-06-30 |
36.53 |
$2.78 |
13.14 |
| 2017-03-31 |
33.37 |
$2.55 |
13.11 |
| 2016-12-31 |
29.83 |
$2.55 |
11.71 |
| 2016-09-30 |
28.17 |
$-1.09 |
0.00 |
| 2016-06-30 |
30.87 |
$-0.44 |
0.00 |
| 2016-03-31 |
28.41 |
$-0.78 |
0.00 |
| 2015-09-30 |
33.58 |
$-1.76 |
0.00 |
| 2015-06-30 |
35.04 |
$1.09 |
32.29 |
| 2014-06-30 |
36.43 |
$1.08 |
33.64 |
| 2013-06-30 |
34.07 |
$4.91 |
6.93 |
| 2012-06-30 |
24.14 |
$4.15 |
5.82 |
| 2012-03-31 |
23.66 |
$4.13 |
5.72 |
| 2011-12-31 |
22.31 |
$4.13 |
5.40 |
| 2011-09-30 |
20.02 |
$4.23 |
4.73 |
| 2011-06-30 |
24.52 |
$4.24 |
5.78 |
| 2011-03-31 |
20.78 |
$4.23 |
4.91 |
| 2010-12-31 |
19.02 |
$4.23 |
4.49 |
| 2010-09-30 |
19.62 |
$3.64 |
5.40 |
| 2010-06-30 |
17.74 |
$3.51 |
5.06 |
| 2010-03-31 |
21.27 |
$3.64 |
5.85 |
| 2009-12-31 |
22.35 |
$3.64 |
6.15 |
| 2009-09-30 |
21.03 |
0 |
0.00 |
| 2009-06-30 |
16.79 |
$1.87 |
8.98 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$140.757B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
